Stephen Baylin, M.D.
Co-leader, Van Andel Institute–Stand Up To Cancer Epigenetics Dream Team
Director’s Scholar and Professor, Department of Epigenetics
Primary appointment: Johns Hopkins University
Dr. Stephen Baylin earned his M.D. from Duke University in Durham, N.C. in 1968 and completed his internship and first year of residency at the university. He then served as a staff associate at the National Institutes of Health’s National Heart and Lung Institute for two years before returning to Johns Hopkins to complete his residency and fellowship. He was appointed as an assistant professor of medicine at Johns Hopkins in 1974 and rose through the ranks, becoming a professor of oncology in 1986 and a professor of medicine in 1990. In 1991, he was appointed chief of the Tumor Biology Division and, the following year, was named as the associate director for research at the Johns Hopkins Oncology Center. He is currently Virginia and D.K. Ludwig Professor for Cancer Research in the Oncology Department and co-head of Cancer Biology at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
Dr. Baylin has earned numerous prestigious honors, including the 2004 Investigator of the Year Award from NCI SPORE; the 2005 Shubitz Cancer Research Prize from the University of Chicago; and the 2009 Kirk A. Landon-AACR Prize for Basic and Translational Cancer Research, together with Van Andel Institute (VAI) Chief Scientific Officer Dr. Peter A. Jones. In 2011, Drs. Baylin and Jones were jointly awarded the American Cancer Society’s Medal of Honor. He was elected to the National Academy of Sciences in 2017.
He has authored or co-authored more than 450 publications and served as associate editor of Cancer Research. Dr. Baylin also served on the board of the American Association for Cancer Research Board of Directors from 2004 to 2007, and was the leader of the first SU2C Epigenetics Dream Team, launched in 2009.
He has received numerous honors and accolades, including the 2011 American Cancer Society Medal of Honor, which he shared with Dr. Peter A. Jones; election as a fellow of the American Association of Cancer Research Academy in 2014; and election as a member of the National Academy of Sciences in 2017.
In 2015, he accepted an appointment at VAI as co-leader of the VAI–SU2C Epigenetics Dream Team, which he leads with Dr. Jones, and as a professor in the Center for Epigenetics. In addition to his work at VAI, Dr. Baylin continues his work at Johns Hopkins
Recent News & PressLearn More
Coriell Institute for Medical Research, Van Andel Institute awarded estimated $12.4 million SPORE grant from National Cancer Institute
Van Andel Institute scientists win Team Science Awards from American Association for Cancer Research
Blocking epigenetic “Swiss army knife” may be a new strategy for treating colorectal cancer
Three Van Andel Research Institute scientists named to list of most cited researchers in the world
Stand Up To Cancer awards $5.5 million to VARI for cancer clinical trials to enhance immunotherapy
VARI cancer researcher elected to National Academy of Sciences
We’re raising thousands to save millions.
We’re turning hope into action for the millions of people around the world affected by diseases like cancer and Parkinson’s. Find out how you can help us make a difference.
- 118 papers published in 2022
- 48 papers in high-impact journals in 2022
- 42 clinical trials launched
RESEARCH FOCUS AT VAI
The Van Andel Institute–Stand Up to Cancer (VAI–SU2C) Epigenetics Dream Team is a multi-institutional effort to develop new epigenetic therapies to combat cancer, and to move promising therapies to clinical trials.
Epigenetics is the study of how the packaging and modification of DNA influences which genes are used or kept silent in a particular cell. By better understanding normal epigenetic processes, scientists can identify errors in epigenetic modifications that lead to the development and progression of cancer. Epigenetic therapies work by correcting these errors and have the potential to directly treat cancer and to sensitize patients to chemotherapy or radiation, which makes these therapies more effective.
The VAI–SU2C Epigenetics Dream Team is headquartered at VAI in Grand Rapids, Michigan, and includes members from Johns Hopkins University, Garvan Institute of Medical Research, Indiana University, Memorial Sloan Kettering Comprehensive Cancer Center, Fox Chase Cancer Center/Temple University, University of Maryland, University of Southern California and Rigshospitalet/University of Copenhagen. The American Association for Cancer Research (AACR), as SU2C’s scientific partner, reviews projects and provides objective scientific oversight
Selected publications from 2015 onward are listed. For more publications, please see Google Scholar.
Kong X*, Chen J*, Xie W*, Brown SM, Cai Y, Wu K, Fan D, Nie Y, Yegnasubramanian S, Tiedemann RL, Tao Y, Yen RWC, Topper MJ, Zahnow CA, Easwaran H, Rothbart SB#, Xia L#, Baylin SB#. 2019. Defining UHRF1 domains that support maintenance of human colon cancer DNA methylation and oncogenic properties. Cancer Cell.
*These authors contributed equally
Selected as a paper of the month by National Institute of Environmental Health Sciences
Tao Y, Kang B, Petkovich DA, Bhandari YR, In J, Stein-O’Brien G, Kong X, Xie W, Zachos N, Maegawa S, Brown S, Chiu Yen RWC, Shao X, Thakor J, Lu Z, Cai Y, Zhang Y, Gonzalez IM, Peinado MA, Zahnow CA, Ahuja N, Fertig E, Issa JP, Baylin SB, Easwaran H. 2019. Aging-like spontaneous epigenetic silencing facilitates Wnt activation, stemness and BrafV600E-induced tumorigenesis. Cancer Cell 35(2):315–326.
Papp E, Hallberg D, Konecny GE, Bruhm DC, Adleff V, Noë M, Kagiampakis I, Palsgrove D, Conklin D, Kinose Y, White JR, Press MF, Drapkin R, Easwaran H, Baylin SB, Slamon D, Velculescu VE, Scharpf RB. 2018. Integrated genomic, epigenomic, and expression analyses of ovarian cancer cell lines. Cell Rep 25(9):2617–2633.
Zhang H, Pandey S, Travers M, Sun H, Morton G, Madzo J, Chung W, Khowsathit J, Perez-Leal O, Barrero CA, Merali C, Okamoto Y, Sato T, Pan J, Garriga J, Bhanu NV, Simithy J, Patel B, Huang J, Raynal NJ, Garcia BA, Jacobson MA, Kadoch C, Merali S, Zhang Y, Childers W, Abou-Gharbia M, Karanicolas J, Baylin SB, Zahnow CA, Jelinek J, Graña X, Issa JJ. 2018. Targeting CDK9 reactivates epigenetically silenced genes in cancer. Cell 175(5):1244–1258.e26.
The Cancer Genome Atlas Research Network. 2018. Somatic mutational landscape of splicing factor genes and their functional consequences across 33 cancer types. Cell Rep 23(1):282–296.e4.
Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Mazurek S, Mishra L, Heyn H, Krasnitz A, Godwin AK, Lazar AJ; Cancer Genome Atlas Research Network, Stuart JM, Hoadley KA, Laird PW, Noushmehr H, Wiznerowicz M. 2018. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell 173(2):338–354.e15.
Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Houlahan KE, Jayasinghe R, Wang LB, Zhou DC, Liu D, Cao S, Kim YW, Koire A, McMichael JF, Hucthagowder V, Kim TB, Hahn A, Wang C, McLellan MD, Al-Mulla F, Johnson KJ, Cancer Genome Atlas Research Network, Lichtarge O, Boutros PC, Raphael B, Lazar AJ, Zhang W, Wendl MC, Govindan R, Jain S, Wheeler D, Kulkarni S, Dipersio JF, Reimand J, Meric-Bernstam F, Chen K, Shmulevich I, Plon SE, Chen F, Ding L. 2018. Pathogenic germline variants at 10,389 adult cancers. Cell 173(2):355–370.e14.
Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Gao J, Gao Q, Wang F, Liu EM, Mularoni L, Rubio-Perez C, Nagarajan N, Cortés-Ciriano I, Zhou DC, Liang WW, Hess JM, Yellapantula VD, Tamborero D, Gonzalez-Perez A, Suphavilai C, Ko JY, Khurana E, Park PJ, Van Allen EM, Liang H, MC3 Working Group, Cancer Genome Atlas Research Network, Lawrence MS, Godzik A, Lopez-Bigas N, Stuart J, Wheeler D, Getz G, Chen K, Lazar AJ, Mills GB, Karchin R, Ding L. 2018. Comprehensive characterization of cancer driver genes and mutations. Cell 173(2):371–385.e18.
Chen H, Li C, Peng X, Zhou Z, Weinstein JN; Cancer Genome Atlas Research Network, Liang H. 2018. A pan-cancer analysis of enhancer expression in nearly 9,000 patient samples. Cell 173(2):386–399.e12.
Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Thorsson V; Cancer Genome Atlas Research Network, Hu H. 2018. An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell 173(2):400–416.e11.
Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Sivakumar IKA, Gentles AJ, Malhotra R, Farshidfar F, Colaprico A, Parker JS, Mose LE, Vo NS, Liu J, Liu Y, Rader J, Dhankani V, Reynolds SM, Bowlby R, Califano A, Cherniack AD, Anastassiou D, Bedognetti D, Rao A, Chen K, Krasnitz A, Hu H, Malta TM, Noushmehr H, Pedamallu CS, Bullman S, Ojesina AI, Lamb A, Zhou W, Shen H, Choueiri TK, Weinstein JN, Guinney J, Saltz J, Holt RA, Rabkin CE, Cancer Genome Atlas Research Network, Lazar AJ, Serody JS, Demicco EG, Disis ML, Vincent BG, Shmulevich L. 2018. The immune landscape of cancer. Immunity 48(4):812–830.e14.
The Cancer Genome Atlas Research Network. 2018. The Cancer Genome Atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep 23(1):313–326.
Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer HN, Lyons JF, Baylin SB, Matei D, Nakshatri H, Rassool FV, Miller KD, Nephew KP. 2018. An effective epigenetic-PARP inhibitor combination therapy for breast and ovarian cancers independent of BRCA-mutations. Clin Cancer Res 24(13):3163–3175.
Xie W, Kagiampakis I, Pan L, Zhang YW, Murphy L, Tao Y, Kong X, Kang BH, Xia L, Carvalho F, Sen S, Yen R-W C, Zahnow CA, Ahuja N, Baylin SB, Easwaran H. 2018. DNA methylation patterns separate senescence from transformation potential and indicate cancer risk. Cancer Cell 33(2):309–321.
Ye F, Kong X, Zhang H, Liu Y, Shao Z, Jin J, Cai Y, Zhang R, Li L, Zhang YW, Liu YC, Zhang C, Xie W, Yu K, Ding H, Zhao K, Chen S, Jiang H, Baylin SB, Luo C. 2018. Biochemical studies and molecular dynamic simulations reveal the molecular basis of conformational changes in DNA methyltransferase-1 (DNMT1). ACS Chem Biol 13(3):772–781.
Szczepny A, Carey K, McKenzie L, Jayasekara WSN, Rossello F, Gonzalez-Rajal A, McCaw AS, Popovski D, Wang D, Sadler AJ, Mahar A, Russell PA, Wright G, McCloy RA, Garama DJ, Gough DJ, Baylin SB, Burgess A, Cain JE, Watkins DN. 2018. The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53. Oncogene 37(14):1939–1948.
Leadem BR, Kagiampakis I, Wilson C, Cheung TK, Arnott D, Trojer P, Classon M, Easwaran H, Baylin SB. 2018. A KDM5 inhibitor increases global H3K4 trimethylation occupancy and enhances the biological efficacy of 5-AZA-2’-deoxycytidine. Cancer Res 78(5):1127–1139.
Liu M, Thomas SL, DeWitt AK, Zhou W, Madaj ZB, Ohtani H, Baylin SB, Liang G, Jones PA. 2018. Dual inhibition of DNA and histone methyltransferases increases viral mimicry in ovarian cancer cells. Cancer Res 78(20):5754–5766.
Stone ML, Chiappinelli KB, Li H, Murphy LM, Travers ME, Topper M, Mathios D, Lim M, Shih I-M, Wang T-L, Hung C-F, Bhargava V, Wiehagen KR, Cowley GS, Bachman KE, Strick R, Strissel PL, Baylin SB, Zahnow CA. 2017. Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden. Proc Natl Acad Sci U S A 114(51):E10981–E10990.
Topper MJ, Vaz M, Chiappinelli KB, DeStefano Shields C, Wenzel A, Hicks J, Ballew M, Stone M, Tran PT, Zahnow CA, Hellmann MD, Strissel PL, Strick R, Baylin SB. 2017. A combination epigenetic therapy ties blocking MYC to reversing immune evasion and treating lung cancer. Cell 171(6):1284–1300.
Cancer Genome Atlas Research Network. 2017. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell 171(3):540–556.
Vaz M, Hwang SY, Kagiampakis I, Patil A, Phallen J, O’Hagan HM, Murphy L, Zahnow CA, Gabrielson E, Velculescu VE, Easwaran HP, Baylin SB. 2017. Chronic cigarette smoke-induced epigenomic changes precede sensitization of human bronchial epithelial cells to single step transformation by KRAS mutations. Cancer Cell 32(3):360–376.
Cancer Genome Atlas Research Network. 2017. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell 31(3):411–423.
Xia L, Huang W, Bellani M, Seidman MM, Wu K, Fan D, Nie Y, Cai Y, Zhang YW, Yu L, Li H, Zahnow CA, Xie W, Yen R-WC, Rassool FV, Baylin SB. 2017. CHD4 has oncogenic functions in initiating and maintaining epigenetic suppression of multiple tumor suppressor genes. Cancer Cell 31(5):653–668.e7.
Cai Y, Tsai H-C, Wang W, Yen R-WC, Xia L, Zhang YW, Baylin SB. 2017. Critical threshold levels of DNA methyltransferase 1 are required to maintain DNA methylation across the genome in human cancer cells. Genome Res 27(4):533–544.
Cancer Genome Atlas Research Network. 2017. Integrated genomic and molecular characterization of cervical cancer. Nature 543(7645):378–38.
Cancer Genome Atlas Research Network. 2017. Integrated genomic characterization of oesophageal carcinoma. Nature 541(7636):169–175.
Hulbert A, Jusue-Torres, Stark A, Chen C, Rodgers K, Lee B, Griffin C, Yang A, Huang P, Wrangle J, Belinsky SA, Wang TH, Yang SC, Baylin SB, Brock MV, Herman JG. 2017. Early detection of lung cancer using DNA promoter hypermethylation in plasma and sputum. Clin Cancer Res 23(8):1998–2005.
Zhang YW, Wang Z, Xie W, Xia L, Easwaran H, Yen R-WC, Baylin SB. 2017. Acetylation enhances TET2 function in protecting against abnormal DNA methylation during oxidative stress. Mol Cell 65(2):323–335.
Azad NS, El-Khoueiry A, Yin J, Oberg AL, Flynn P, Adkins D, Sharma A, Weisenberger DJ, Brown T, Medvari P, Jones PA, Easwaran H, Kamel I, Bahary N, Kim G, Picus J, Pitot HC, Erlichman C, Donehower R, Shen H, Laird PW, Piekarz R, Baylin S, Ahuja N. 2017. Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat; a phase 2 consortium/stand Up 2 cancer study. Oncotarget 8(21):35326–35338.
Anagnostou V, Smith KN, Forde PM, Niknafs N, Bhattacharya R, White J, Zhang T, Adleff V, Phallen J, Wali N, Hruban C, Guthrie VB, Rodgers K, Naidoo J, Georgiades C, Verde F, Li QK, Gabrielson E, Brock MV, Zahnow CA, Baylin SB, Scharpf R, Brahmer J, Karchin R, Pardoll D, Velculescu VE. 2017. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov 7(3):264–276.
Connolly R, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater S, Powers P, Wolff AC, Fetting JH, Brufsky AM, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia A, Jones PA, Baylin SB, Davidson NE, Zahnow C, Stearns V. 2017. Combination epigenetic therapy in advanced breast cancer with 5-Azacitidine and entinostat: A phase II National Cancer Institute/Stand Up to Cancer study. Clin Cancer Res 23(11):2691–2701.
Fu T, Liu Y, Li K, Wan W, Pappou EP, Iacobuzio-Donahue CA, Kerner Z, Baylin SB, Wolfgang CL, Ahuja N. 2016. Tumors with unmethylated MLH1 and the CpG island methylator phenotype are associated with a poor prognosis in stage II colorectal cancer patients. Oncotarget 7(52):86480–86489.
Zimmerlin L, Park TS, Huo JS, Verma K, Pather SR, Talbot CC Jr, Agarwal J, Steppan D, Zhang YW, Considine M, Guo H, Zhong X, Gutierrez C, Cope L, Canto-Soler MV, Friedman AD, Baylin SB, Zambidis ET. 2016. Tankyrase inhibition promotes a stable human naïve pluripotent state with improved functionality. Development 143(23):4368–4380.
Strick R, Strissel PL, Baylin SB, Chiappinelli KB. 2015. Unraveling the molecular pathways of DNA methylation inhibitors: human endogenous retroviruses induce the innate immune response in tumors. Oncoimmunology 5(5):e1122160.
Muvarak N, Chowdhury K, Xia L, Robert C, Choi EY, Cai Y, Bellani M, Zou Y, Singh ZN, Duong VH, Rutherford T, Nagaria1 P, Bentzen SM, Seidman MM, Baer MR, Lapidus RG, Baylin SB, Rassool FV. 2016. Enhancing the cytotoxic effects of PARP inhibitors with DNA demethylating agents – A potential therapy for cancer. Cancer Cell 30:637–650.
Fu T, Sharmab A, Xie F, Liu Y, Li K, Wan W, Baylin SB, Wolfgang CL, Ahuja N. 2016. Methylation of MGMT is associated with poor prognosis in patients with stage III duodenal adenocarcinoma. PLoS One 11(9):e0162929.
Sen S, Block KF, Pasini A, Baylin SB, Easwaran H. 2016. Genome-wide positioning of bivalent mononucleosomes. BMC Med Genomics 9(1):60.
Jones PA, Issa J-P J, Baylin SB. 2016. Targeting the cancer epigenome for therapy. Nat Rev Genet 17(10):630–461.
Liu M, Ohtani H, Zhou W, Ørskov AD, Charlet J, Zhang YW, Shen H, Baylin SB, Liang G, Grønbæk K, Jones PA. 2016. Vitamin C increases viral mimicry induced by 5-aza-2′-deoxycytidine. Proc Natl Acad Sci U S A 113(37):10238–10244.
Campbell JD, Alexandrov A, Kim J, Wala J, Berger AH, Pedamallu CS, Shukla SA, Guo G, Brooks AN, Murray BA, Imielinski M, Hu X, Ling S, Akbani R, Rosenberg M, Cibulskis C, Ramachandran A, Collisson EA, Kwiatkowski DJ, Lawrence MS, Weinstein JN, Verhaak RG, Wu CJ, Hammerman PS, Cherniack AD, Getz G; Cancer Genome Atlas Research Network, Artyomov MN, Schreiber R, Govindan R, Meyerson M. Zenklusen JC, Zhang J, Felau I, Demchok JA, Yang L, Wang Z, Ferguson ML, Tarnuzzer R, Hutter CM, Sofia HJ, Pihl T, Wan Y, Chudamani S, Liu J, Sun C, Naresh R, Lolla L, Wu Y, Creighton CJ, Rathmell WK, Auman JT, Balu S, Bodenheimer T, Hayes DN, Hoadley KA, Hoyle AP, Jones CD, Jefferys SR, Meng S, Mieczkowski PA, Mose LE, Perou CM, Roach J, Shi Y, Simons JV, Skelly T, Soloway MG, Tan D, Wu J, Veluvolu U, Parker JS, Wilkerson MD, Boice L, Huang M, Thorne LB, Getz G, Noble MS, Zhang H, Heiman DI, Cho J, Gehlenborg N, Saksena G, Voet D, Lin P, Frazer S, Kim J, Lawrence MS, Chin L, Tsao MS, Allison F, Chadwick D, Muley T, Meister M, Dienemann H, Kucherlapati R, Park P, Bowen J, Gastier-Foster JM, Gerken M, Leraas KM, Lichtenberg TM, Ramirez NC, Wise L, Zmuda E, Stuart J, Collisson E, Peifer M, Kwiatkowski D, Campbell JD, Murray BA, Cherniack AD, Berger AH, Sougnez C, Schumacher SE, Shih J, Beroukhim R, Zack TI, Gabriel SB, Meyerson M, Byers LA, Davidsen T, Laird PW, Weisenberger DJ, Van Den Berg DJ, Bootwalla MS, Lai PH, Maglinte DT, Baylin SB, Herman JG, Danilova L, Cope L, Crain DJ, Curley E, Gardner J, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton C, Shelton T, Sherman M, Yena P, Mills GB. 2016. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas. Nat Genet 48(6):607–616.
Baylin SB, Jones PA. 2016. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol 8(9): pii:a019505.
Chiappinelli KB, Zahnow CA, Ahuja N, Baylin SB. 2016. Combining epigenetic and immunotherapy to combat cancer. Cancer Res 76(7):1683–1689.
Baylin SB. 2016. Jacob, Monod, the Lac Operon, and the PaJaMa Experiment-Gene Expression circuitry changing the face of cancer research. Cancer Res 76(8):2060–2062.
Viúdez A, Carvalho FL, Maleki Z, Zahurak M, Laheru D, Stark A, Azad NZ, Wolfgang CL, Baylin S, Herman JG, De Jesus-Acosta A. 2016. A new immunohistochemistry prognostic score (IPS) for recurrence and survival in resected pancreatic neuroendocrine tumors (PanNET). Oncotarget 7(18):24950–24961.
Ceccarelli M, Barthel FP, Malta TM, Sabedot TS, Salama SR, Murray BA, Morozova O, Newton Y, Radenbaugh A, Pagnotta SM, Anjum S, Wang J, Manyam G, Zoppoli P, Ling S, Rao AA, Grifford M, Cherniack AD, Zhang H, Poisson L, Carlotti CG Jr, Tirapelli DP, Rao A, Mikkelsen T, Lau CC, Yung WK, Rabadan R, Huse J, Brat DJ, Lehman NL, Barnholtz-Sloan JS, Zheng S, Hess K, Rao G, Meyerson M, Beroukhim R, Cooper L, Akbani R, Wrensch M, Haussler D, Aldape KD, Laird PW, Gutmann DH; TCGA Research Network, Noushmehr H, Iavarone A, Verhaak RG, Anjum S, Arachchi H, Auman JT, Balasundaram M, Balu S, Barnett G, Baylin S, Bell S, Benz C, Bir N, Black KL, Bodenheimer T, Boice L, Bootwalla MS, Bowen J, Bristow CA, Butterfield YS, Chen QR, Chin L, Cho J, Chuah E, Chudamani S, Coetzee SG, Cohen ML, Colman H, Couce M, D’Angelo F, Davidsen T, Davis A, Demchok JA, Devine K, Ding L, Duell R, Elder JB, Eschbacher JM, Fehrenbach A, Ferguson M, Frazer S, Fuller G, Fulop J, Gabriel SB, Garofano L, Gastier-Foster JM, Gehlenborg N, Gerken M, Getz G, Giannini C, Gibson WJ, Hadjipanayis A, Hayes DN, Heiman DI, Hermes B, Hilty J, Hoadley KA, Hoyle AP, Huang M, Jefferys SR, Jones CD, Jones SJ, Ju Z, Kastl A, Kendler A, Kim J, Kucherlapati R, Lai PH, Lawrence MS, Lee S, Leraas KM, Lichtenberg TM, Lin P, Liu Y, Liu J, Ljubimova JY, Lu Y, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, McGraw M, McPherson C, Meng S, Mieczkowski PA, Miller CR, Mills GB, Moore RA, Mose LE, Mungall AJ, Naresh R, Naska T, Neder L, Noble MS, Noss A, O’Neill BP, Ostrom QT, Palmer C, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Pierson CR, Pihl T, Protopopov A, Radenbaugh A, Ramirez NC, Rathmell WK, Ren X, Roach J, Robertson AG, Saksena G, Schein JE, Schumacher SE, Seidman J, Senecal K, Seth S, Shen H, Shi Y, Shih J, Shimmel K, Sicotte H, Sifri S, Silva T, Simons JV, Singh R, Skelly T, Sloan AE, Sofia HJ, Soloway MG, Song X, Sougnez C, Souza C, Staugaitis SM, Sun H, Sun C, Tan D, Tang J, Tang Y, Thorne L, Trevisan FA, Triche T, Van Den Berg DJ, Veluvolu U, Voet D, Wan Y, Wang Z, Warnick R, Weinstein JN, Weisenberger DJ, Wilkerson MD, Williams F, Wise L, Wolinsky Y, Wu J, Xu AW, Yang L, Yang L, Zack TI, Zenklusen JC, Zhang J, Zhang W, Zhang J, Zmuda E. 2016. Molecular profiling reveals biologically discrete subsets and pathways of progression in diffuse glioma. Cell 164(3):550–563.
Ahuja N, Sharma AR, Baylin SB. 2016. Epigenetic therapeutics: A new weapon in the war against cancer. Annu Rev Med 67:73–89.
Baylin SB. 2015. Interview with Stephen B. Baylin. Epigenomics 7(6):881–883.
Raynal NJ, Lee JT, Wang Y, Beaudry A, Madireddi P, Garriga J, Malouf GG, Dumont S, Dettman EJ, Gharibyan V, Ahmed S, Chung W, Childers WE, Abou-Gharbia M, Henry RA, Andrews AJ, Jelinek J, Cui Y, Baylin SB, Gill D, Issa JJ. 2015. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Res 76(6):1494–1505.
Cancer Genome Atlas Research Network. 2015. The molecular taxonomy of primary prostate cancer. Cell 163(4):1011–1025.
Cancer Genome Atlas Research Network. 2015. Comprehensive molecular characterization of papillary renal-cell carcinoma. N Engl J Med 374(2):134–145.
Chiappinelli KB, Strissel PL, Desrichard A, Li H, Henke C, Akman B, Hein A, Rote NS, Cope LM, Snyder A, Makarov V, Buhu S, Slamon DJ, Wolchok JD, Pardoll DM, Beckmann MW, Zahnow CA, Mergoub T, Chan TA, Baylin SB, Strick R. 2015. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162:974–986.
Ding N, Bonham EM, Hannon BE, Amick TR, Baylin SB, O’Hagan HM. 2015. Mismatch repair proteins recruit DNA methyltransferase 1 to sites of oxidative DNA damage. J Mol Cell Biol 8(3):244–254.
Cancer Genome Atlas Network. 2015. Genomic classification of cutaneous melanoma. Cell 161(7):1681–1696.
Cancer Genome Atlas Research Network. 2015. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372(26):2481–2498.
Calmon MF, Jeschke J, Zhang W, Dhir M, Siebenkäs C, Herrera A, Tsai HC, O’Hagan HM, Pappou EP, Hooker CM, Fu T, Schuebel KE, Gabrielson E, Rahal P, Herman JG, Baylin SB, Ahuja N. 2015. Epigenetic silencing of neurofilament genes promotes an aggressive phenotype in breast cancer. Epigenetics 10(7):622–632.
Juo YY, Gong XJ, Mishra A, Cui X, Baylin SB, Azad NS, Ahuja N. 2015. Epigenetic therapy for solid tumors: from bench science to clinical trials. Epigenomics 7(2):215–235.
Fu T, Pappou EP, Guzzetta AA, Calmon MF, Sun L, Herrera A, Li F, Wolfgang CL, Baylin SB, Iacobuzio-Donahue CA, Tong W, Ahuja N. 2015. IGFBP-3 gene methylation in primary tumor predicts recurrence of stage II colorectal cancers. Ann Surg 263(2):337–344.
Cancer Genome Atlas Research Network. 2015. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517(7536):576–582.